1,000 Shares in Shire PLC (SHPG) Purchased by Wolverine Asset Management LLC
Wolverine Asset Management LLC purchased a new position in shares of Shire PLC (NASDAQ:SHPG) during the second quarter, HoldingsChannel reports. The fund purchased 1,000 shares of the biopharmaceutical company’s stock, valued at approximately $168,000.
A number of other large investors have also modified their holdings of SHPG. Rockefeller Capital Management L.P. purchased a new stake in Shire during the first quarter worth about $113,097,000. LMR Partners LLP purchased a new stake in Shire during the second quarter worth about $55,664,000. SG Americas Securities LLC increased its stake in Shire by 1,634.4% during the second quarter. SG Americas Securities LLC now owns 193,547 shares of the biopharmaceutical company’s stock worth $32,671,000 after purchasing an additional 182,388 shares during the period. Prosight Management LP purchased a new stake in Shire during the first quarter worth about $21,828,000. Finally, Delek Group Ltd. increased its stake in Shire by 101.0% during the first quarter. Delek Group Ltd. now owns 252,750 shares of the biopharmaceutical company’s stock worth $37,797,000 after purchasing an additional 127,000 shares during the period. Institutional investors own 17.86% of the company’s stock.
SHPG stock opened at $176.94 on Monday. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.02 and a current ratio of 1.55. Shire PLC has a fifty-two week low of $123.73 and a fifty-two week high of $177.75. The company has a market cap of $52.51 billion, a P/E ratio of 11.68, a PEG ratio of 1.53 and a beta of 1.22.
The company also recently announced a dividend, which will be paid on Friday, October 19th. Investors of record on Friday, September 7th will be paid a dividend of $0.168 per share. The ex-dividend date is Thursday, September 6th. Shire’s payout ratio is 2.24%.
A number of analysts have issued reports on the stock. Evercore ISI lowered shares of Shire from an “outperform” rating to a “market perform” rating and set a $196.00 price target on the stock. in a research note on Tuesday, September 4th. Sanford C. Bernstein lowered shares of Shire from an “outperform” rating to a “market perform” rating in a research note on Tuesday, September 4th. ValuEngine upgraded shares of Shire from a “sell” rating to a “hold” rating in a research note on Friday, August 24th. Royal Bank of Canada set a $188.00 price target on shares of Shire and gave the stock a “buy” rating in a research note on Thursday, July 19th. Finally, BidaskClub upgraded shares of Shire from a “sell” rating to a “hold” rating in a research note on Thursday. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and ten have issued a buy rating to the company. Shire has an average rating of “Hold” and an average target price of $200.75.
Shire Company Profile
Shire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells medicines for rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology.
Read More: How to Use the New Google Finance Tool
Want to see what other hedge funds are holding SHPG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Shire PLC (NASDAQ:SHPG).
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.